Infection Control and Disease Surveillance in Africa

By Crystal Lubbe

December 10, 2024

cross-border health security

The topic of National borders as a critical frontline in containing deadly infections is increasingly significant for public health initiatives. The Africa CDC plays a crucial role in addressing infection prevention and control measures linked to these borders. Their approach emphasises the necessity of robust systems and collaborations that allow for effective management of health threats that cross national boundaries.

Infection Prevention and Control (IPC) Legal Framework

The Africa CDC has developed a comprehensive IPC Legal Framework aimed at strengthening infection prevention and control measures across African Union Member States. This framework incorporates six critical areas:
– Establishing national IPC programs
– Developing evidence-based guidance
– Training and educating personnel
– Conducting surveillance for healthcare-associated infections (HAIs)
– Developing systems to monitor compliance with laws
– Mandating specific staffing and infrastructure changes in hospitals.

Implementation and Support

The Africa CDC is actively assisting Member States in implementing this IPC Legal Framework through financial, technical, and collaborative support. Workshops and joint efforts with countries like Cameroon, Liberia, Malawi, and Nigeria have been conducted to review and enhance existing IPC programs and legal instruments.

Disease Surveillance and Health Security

In collaboration with the World Health Organization (WHO) and other partners, the Africa CDC has launched initiatives to strengthen disease surveillance and health security across Africa. This includes the Health Security Partnership designed to enhance integrated disease surveillance, event-based surveillance, genomic surveillance, and epidemic intelligence. Such partnerships are invaluable for swiftly detecting and addressing health security threats, especially since national borders serve as a critical frontline in containing deadly infections.

Cross-Border Disease Control

National borders are crucial in containing infections, making RISLNET vital. It harmonises labs, integrates surveillance, and boosts cross-border collaboration to combat regional health challenges.

Multi-Sectoral Collaboration

The Africa CDC promotes a multi-sectoral approach to align IPC measures with regional and international standards. This collaborative effort is crucial for effective implementation and fostering a healthier and safer environment across the continent.

In summary, the Africa CDC’s efforts in infection prevention and control, disease surveillance, and health security therefore, illustrate the vital role of National borders as a critical frontline in containing deadly infections. Their documented initiatives highlight the importance of robust legal frameworks, cross-border collaboration, and multi-sectoral approaches to effectively combat health threats.

Reference url

Recent Posts

Cemiplimab Cervical Cancer Access
Cemiplimab Cervical Cancer Access Navigating Treatment and Value

By João L. Carapinha

June 24, 2026

Cemiplimab Cervical Cancer Access has been endorsed by NICE for adults with recurrent or metastatic cervical cancer that has progressed after platinum-based chemotherapy, provided patients have not previously received immunotherapy. The final draft guidance confirms that this PD-1 inhibitor deliv...
pharmaceutical innovation ROI
Shifting Perspectives on Pharmaceutical Innovation ROI as Socioeconomic Investment

By João L. Carapinha

June 24, 2026

Pharmaceutical innovation ROI is shifting from a narrow budget metric to a powerful indicator of societal return. Between 2014 and 2024, a 3.1-year rise in utilization-weighted mean drug vintage across 29 European countries prevented 1.83 million years of life lost before age 85 and saved 20.9 mi...
CAR T-Cell Therapy
Pioneering CAR T-Cell Therapy for Advanced Gastric Cancer

By João L. Carapinha

June 24, 2026

CAR T-Cell Therapy has reached a historic milestone with the approval of satri-cel, the world’s first authorized CAR T treatment for any solid tumor. The therapy targets Claudin18.2-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma that has progressed after at l...